Our proprietary technology platform systematically leverages the powerful tools of big genomic data and AI to build molecular networks: a set of interconnected potential therapeutic targets.
Harnessing disease molecular networks, we screen both generic compounds and NCEs to develop novel drug combinations hitting multiple highly relevant disease targets.
Formulated with optimal doses of their components, our products are expected to be safer and more effective than existing therapies.
Find here the recording of the webcast during which our CEO and CMO presented and discussed the results of an interim analysis of our PXT3003 open-label Phase III Extension study
Pharnext will attend the 24th Neuromuscular Days in Marseille, France
Pharnext will attend the AANEM 2021 Annual Meeting to be held in Aurora, Colorado (US)
Pharnext will attend the RARE 2021 Annual Meeting which is going virtual